Matches in SemOpenAlex for { <https://semopenalex.org/work/W2983203485> ?p ?o ?g. }
- W2983203485 endingPage "3820" @default.
- W2983203485 startingPage "3820" @default.
- W2983203485 abstract "Premature discontinuation of asparaginase reduces cure rate in contemporary acute lymphoblastic leukemia (ALL) treatment. One of the commonest causes of asparaginase truncation is asparaginase-associated pancreatitis (AAP). We prospectively registered AAP during treatment of 2,448 consecutive Nordic/Baltic ALL patients aged 1.0-45.9 years treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol (7/2008-10/2018). The Day 280 cumulative incidence of first-time AAP (including 99% (167/168) of AAP events at this time point) was 8.3% (95% confidence interval (CI) 7.0-9.9) with a median time of 104 days (interquartile range (IQR) 70-145) from ALL diagnosis to AAP, with a median of 10 days (IQR 6-13) from last asparaginase exposure, and after a median number of five asparaginase doses (IQR 3-7, max 14 doses). All patients received polyethylene glycol conjugated Escherichia coli-derived asparaginase as standard treatment. Eighty-five percent (140/164, unknown in N=4) of AAP events were severe (AAP-associated symptoms and/or pancreatic enzymes >3x upper normal limit lasting >72 hours or with hemorrhagic pancreatitis, pancreatic abscess, or pseudocyst). Four age groups were defined: 1.0-4.9, 5.0-8.9, 9.0-16.9, and 17.0-45.9 years-each containing approximately 25% of the AAP events. Compared with patients aged 1.0-4.9 years, adjusted (sex, immunophenotype, and white blood cell count) hazard ratios (HR) of AAP were associated with higher age (5.0-8.9 years: HR 2.3, 95% CI 1.5-3.6, P<.0001; 9.0-16.9 years: HR 2.5, 95% CI 1.6-3.8, P<.0001; and 17.0-45.9 years: HR 2.5, 95% CI 1.6-3.8, P<.0001). When analyzing the odds of developing any AAP-related complication among patients with ≥100 days of follow-up after the AAP diagnosis, older children (≥5.0 years) and adolescents had increased odds of developing any complication compared with younger children aged 1.0-4.9 years, notably a more than six-fold increase among adolescents (5.0-8.9 years: odds ratio (OR) 2.67, 95% CI 1.07-6.68, P=.04 and 9.0-16.9 years: OR 6.52, 95% CI 2.35-18.1, P=.0003)-including acute and permanent insulin need; intensive care unit admission; pancreatic pseudocyst development; recurrent abdominal pain; elevated pancreatic enzymes at last-follow-up; imaging compatible with pancreatitis (pancreatic inflammation/edema/pseudocysts/hemorrhage) at last follow-up; and AAP-related death. Adult age was not associated with development of any AAP-related complication (17.0-45.9 years: OR 2.3, 95% CI 0.9-5.9, P=.07). Three patients aged 8.6, 17.3, and 18.6 years died of first-time AAP within 0-29 days from AAP diagnosis. Of 168 AAP patients, 34 (20%) were re-challenged with asparaginase. Fifty percent (17/34) developed a second episode of AAP-41% being severe (7/17). The median time to a second AAP event from asparaginase re-exposure was 29 days (IQR 16-94) and occurred after a median of two asparaginase doses (range 0-7). Neither age group nor severity of the first AAP was associated with increased hazard of a second AAP event. None of the patients with a second AAP were further re-exposed to asparaginase, and none died of the second AAP. Among a total of 196 ALL relapses, 21 patients have had AAP including 17 patients with asparaginase truncation. However, the hazard of relapse (age- and sex-adjusted) was not increased among AAP patients with asparaginase truncation versus AAP patients with asparaginase re-exposure (5.0-year cumulative incidence of relapse: 13.2% versus 14.2%) (HR 1.0, 95% CI 0.3-3.1, P=1.0). When analyzing time to relapse among AAP patients versus non-AAP patients, no difference in hazard of relapse was found (HR 2.0, 95% CI 0.8-4.9, P=.2). In conclusion, adolescents and young adults tolerated asparaginase treatment as well as children; however, the risk of AAP was higher for patients older than 5.0 years of age with no difference with increasing age. Despite a low AAP-related mortality, the morbidity was considerable and most profound for patients aged 9.0-16.9 years. Since asparaginase re-exposure was associated with a high risk of a second AAP event and neither AAP development nor AAP-related asparaginase truncation was associated with increased relapse risk, asparaginase re-exposure should be attempted only in patients with a high risk of leukemic relapse. Finally, there is an unmet need for preventive strategies toward AAP. Disclosures Wolthers: Novo Nordisk: Employment." @default.
- W2983203485 created "2019-11-22" @default.
- W2983203485 creator A5007917870 @default.
- W2983203485 creator A5016410234 @default.
- W2983203485 creator A5017466426 @default.
- W2983203485 creator A5019494622 @default.
- W2983203485 creator A5022304220 @default.
- W2983203485 creator A5024957067 @default.
- W2983203485 creator A5029118554 @default.
- W2983203485 creator A5032784001 @default.
- W2983203485 creator A5052149330 @default.
- W2983203485 creator A5052608802 @default.
- W2983203485 creator A5062239086 @default.
- W2983203485 creator A5063115909 @default.
- W2983203485 creator A5066050875 @default.
- W2983203485 creator A5071246354 @default.
- W2983203485 creator A5071720008 @default.
- W2983203485 creator A5072240503 @default.
- W2983203485 creator A5072921521 @default.
- W2983203485 creator A5074845542 @default.
- W2983203485 creator A5075222101 @default.
- W2983203485 creator A5080669001 @default.
- W2983203485 creator A5082379914 @default.
- W2983203485 creator A5083075511 @default.
- W2983203485 creator A5085002313 @default.
- W2983203485 creator A5087038443 @default.
- W2983203485 creator A5090272956 @default.
- W2983203485 date "2019-11-13" @default.
- W2983203485 modified "2023-10-14" @default.
- W2983203485 title "Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years" @default.
- W2983203485 doi "https://doi.org/10.1182/blood-2019-122275" @default.
- W2983203485 hasPublicationYear "2019" @default.
- W2983203485 type Work @default.
- W2983203485 sameAs 2983203485 @default.
- W2983203485 citedByCount "0" @default.
- W2983203485 crossrefType "journal-article" @default.
- W2983203485 hasAuthorship W2983203485A5007917870 @default.
- W2983203485 hasAuthorship W2983203485A5016410234 @default.
- W2983203485 hasAuthorship W2983203485A5017466426 @default.
- W2983203485 hasAuthorship W2983203485A5019494622 @default.
- W2983203485 hasAuthorship W2983203485A5022304220 @default.
- W2983203485 hasAuthorship W2983203485A5024957067 @default.
- W2983203485 hasAuthorship W2983203485A5029118554 @default.
- W2983203485 hasAuthorship W2983203485A5032784001 @default.
- W2983203485 hasAuthorship W2983203485A5052149330 @default.
- W2983203485 hasAuthorship W2983203485A5052608802 @default.
- W2983203485 hasAuthorship W2983203485A5062239086 @default.
- W2983203485 hasAuthorship W2983203485A5063115909 @default.
- W2983203485 hasAuthorship W2983203485A5066050875 @default.
- W2983203485 hasAuthorship W2983203485A5071246354 @default.
- W2983203485 hasAuthorship W2983203485A5071720008 @default.
- W2983203485 hasAuthorship W2983203485A5072240503 @default.
- W2983203485 hasAuthorship W2983203485A5072921521 @default.
- W2983203485 hasAuthorship W2983203485A5074845542 @default.
- W2983203485 hasAuthorship W2983203485A5075222101 @default.
- W2983203485 hasAuthorship W2983203485A5080669001 @default.
- W2983203485 hasAuthorship W2983203485A5082379914 @default.
- W2983203485 hasAuthorship W2983203485A5083075511 @default.
- W2983203485 hasAuthorship W2983203485A5085002313 @default.
- W2983203485 hasAuthorship W2983203485A5087038443 @default.
- W2983203485 hasAuthorship W2983203485A5090272956 @default.
- W2983203485 hasBestOaLocation W29832034851 @default.
- W2983203485 hasConcept C119060515 @default.
- W2983203485 hasConcept C126322002 @default.
- W2983203485 hasConcept C187212893 @default.
- W2983203485 hasConcept C207103383 @default.
- W2983203485 hasConcept C2775967933 @default.
- W2983203485 hasConcept C2778461978 @default.
- W2983203485 hasConcept C2778715236 @default.
- W2983203485 hasConcept C2778904437 @default.
- W2983203485 hasConcept C2781107101 @default.
- W2983203485 hasConcept C2909962599 @default.
- W2983203485 hasConcept C44249647 @default.
- W2983203485 hasConcept C71924100 @default.
- W2983203485 hasConcept C72563966 @default.
- W2983203485 hasConcept C88879693 @default.
- W2983203485 hasConcept C90924648 @default.
- W2983203485 hasConceptScore W2983203485C119060515 @default.
- W2983203485 hasConceptScore W2983203485C126322002 @default.
- W2983203485 hasConceptScore W2983203485C187212893 @default.
- W2983203485 hasConceptScore W2983203485C207103383 @default.
- W2983203485 hasConceptScore W2983203485C2775967933 @default.
- W2983203485 hasConceptScore W2983203485C2778461978 @default.
- W2983203485 hasConceptScore W2983203485C2778715236 @default.
- W2983203485 hasConceptScore W2983203485C2778904437 @default.
- W2983203485 hasConceptScore W2983203485C2781107101 @default.
- W2983203485 hasConceptScore W2983203485C2909962599 @default.
- W2983203485 hasConceptScore W2983203485C44249647 @default.
- W2983203485 hasConceptScore W2983203485C71924100 @default.
- W2983203485 hasConceptScore W2983203485C72563966 @default.
- W2983203485 hasConceptScore W2983203485C88879693 @default.
- W2983203485 hasConceptScore W2983203485C90924648 @default.
- W2983203485 hasIssue "Supplement_1" @default.
- W2983203485 hasLocation W29832034851 @default.
- W2983203485 hasOpenAccess W2983203485 @default.
- W2983203485 hasPrimaryLocation W29832034851 @default.
- W2983203485 hasRelatedWork W1595286375 @default.
- W2983203485 hasRelatedWork W2148911532 @default.